Nano-X Imaging Past Earnings Performance
Past criteria checks 0/6
Nano-X Imaging's earnings have been declining at an average annual rate of -31.8%, while the Healthcare industry saw earnings growing at 7% annually. Revenues have been growing at an average rate of 75% per year.
Key information
-31.8%
Earnings growth rate
-18.5%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 75.0% |
| Return on equity | -31.1% |
| Net Margin | -613.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Apr 05
Nano-X Imaging: System Deployments Finally Begin
Apr 01Nano-X Imaging gains on FDA submission for new digital X-ray technology
Sep 28Nano-X Imaging Q2 Earnings Preview
Aug 15Nano-X: Too Controversial To Buy
Jun 30Nano-X Imaging Q4 2021 Earnings Preview: Insight Coming Regarding This Binary Play
Mar 30Monday's Drop Isn't Likely The Last One For Nano-X
Dec 28Nano-X Imaging Stock Is A No-No Buy
Oct 11We're Interested To See How Nano-X Imaging (NASDAQ:NNOX) Uses Its Cash Hoard To Grow
Aug 20Nanox submits 510(k) application for first version of Nanox.ARC 3-D in U.S.
Jun 17We're Not Worried About Nano-X Imaging's (NASDAQ:NNOX) Cash Burn
May 05Here's What Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Shareholder Ownership Structure Looks Like
Mar 08Nano-X Imaging lower 10% on additional information request by FDA on Nanox.ARC version
Feb 01Nano-X Imaging (NASDAQ:NNOX) Is In A Strong Position To Grow Its Business
Jan 13
Nano-X Imaging and USARAD extend strategic collaboration
Jan 05Nano-X Vision Under The X-Ray
Dec 09What Type Of Shareholders Make Up Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Share Registry?
Nov 21Nano-X Imaging EPS misses by $0.12
Nov 09NANO-X Imaging: Novel Technology Or Outdated Technology?
Nov 02Revenue & Expenses BreakdownBeta
How Nano-X Imaging makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 10 | -61 | 26 | 26 |
| 30 Sep 23 | 10 | -103 | 25 | 26 |
| 30 Jun 23 | 10 | -101 | 29 | 26 |
| 31 Mar 23 | 9 | -103 | 34 | 26 |
| 31 Dec 22 | 9 | -113 | 38 | 27 |
| 30 Sep 22 | 8 | -82 | 49 | 26 |
| 30 Jun 22 | 5 | -77 | 45 | 23 |
| 31 Mar 22 | 3 | -71 | 44 | 21 |
| 31 Dec 21 | 1 | -62 | 42 | 17 |
| 30 Sep 21 | 0 | -59 | 44 | 14 |
| 30 Jun 21 | 0 | -56 | 44 | 12 |
| 31 Mar 21 | 0 | -49 | 39 | 10 |
| 31 Dec 20 | 0 | -44 | 34 | 9 |
| 30 Sep 20 | 0 | -44 | 36 | 8 |
| 30 Jun 20 | 0 | -35 | 28 | 7 |
| 31 Mar 20 | 0 | -29 | 24 | 5 |
| 31 Dec 19 | 0 | -23 | 20 | 3 |
Quality Earnings: NNOX is currently unprofitable.
Growing Profit Margin: NNOX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NNOX is unprofitable, and losses have increased over the past 5 years at a rate of 31.8% per year.
Accelerating Growth: Unable to compare NNOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NNOX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.2%).
Return on Equity
High ROE: NNOX has a negative Return on Equity (-31.09%), as it is currently unprofitable.